A human cell line genetically engineered to produce, store and release insulin in response to blood sugar levels in the human body could eliminate the need for daily injections for insulin-reliant diabetics.
May 23, 2016
1
57
The U.S. Supreme Court on Thursday unanimously threw out attempts to patent human genes, siding with advocates who say the multibillion-dollar biotechnology industry should not have exclusive control over genetic information ...
Jun 13, 2013
31
0
A new gonorrhea treatment, based on an anti-cancer therapy developed by a Buffalo startup company, has successfully eliminated gonococcal infection from female mice and prevented reinfection, according to research published ...
Sep 18, 2013
1
0
A quick, affordable diagnostic test developed by a Washington State University researcher may help curb one of the most prevalent but least discussed sexually transmitted infections.
Mar 27, 2023
0
30
(Medical Xpress)—On April 15, the Supreme Court will hear oral argument in Association for Molecular Pathology v. Myriad Genetics, a case that could answer the question, "Under what conditions, if any, are isolated human ...
Apr 11, 2013
14
0
A long-ignored white blood cell may be central to the immune system overreaction that is the most common cause of death for COVID-19 patients—and University of Michigan researchers found that rod-shaped particles can take ...
Jun 10, 2020
0
264
Over a year into global COVID-19 vaccination efforts the question of whether jab formulas ought to be freely available is still unresolved—and undersupplied countries are turning to workarounds.
Jan 17, 2022
0
19
Supply of cheap, copycat drugs for the developing world could be badly threatened if Swiss firm Novartis wins a challenge to India's patent law, medical charity MSF said on Monday.
Sep 5, 2011
1
0
Sales of cholesterol blockbuster Lipitor plunged by half barely a week after the world's top-selling drug got its first U.S. generic competition, new data show.
Dec 20, 2011
3
0
(AP) -- Lipitor is so valuable that its maker, Pfizer Inc., is practically paying people to keep taking the blockbuster cholesterol medicine after generic competition hits the U.S. market this week.
Nov 29, 2011
0
0
